Abstract
BackgroundKRAS mutations occur in about 15–20% of patients with lung cancer. Due to the small size and smooth surface of KRAS protein, it is difficult to develop KRAS inhibitors. Sotorasib...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
